Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 4/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29730178 | 1.00 | NR1H2 (0.39) | NR1H2NR1H3RBP4RIPK1HTR1A | |
| SCHEMBL22638850 | 1.00 | NR1H2 (0.39) | NR1H2NR1H3RBP4RIPK1HTR1A | |
| SCHEMBL30968257 | 1.00 | NR1H2 (0.39) | NR1H2NR1H3RBP4RIPK1HTR1A | |
| SCHEMBL22638804 | 1.00 | NR1H2 (0.39) | NR1H2NR1H3RBP4RIPK1HTR1A | |
| SCHEMBL22638805 | 1.00 | NR1H2 (0.39) | NR1H2NR1H3RBP4RIPK1HTR1A | |
| SCHEMBL22638974 | 1.00 | NR1H2 (0.39) | NR1H2NR1H3RBP4RIPK1HTR1A | |
| SCHEMBL22638897 | 1.00 | NR1H2 (0.39) | NR1H2NR1H3RBP4RIPK1HTR1A | |
| SCHEMBL22638852 | 1.00 | NR1H2 (0.39) | NR1H2NR1H3RBP4RIPK1HTR1A | |
| SCHEMBL22638952 | 1.00 | NR1H2 (0.39) | NR1H2NR1H3RBP4RIPK1HTR1A | |
| SCHEMBL20166537 | 0.88 | RIPK1 (0.51) | NR1H2NR1H3RIPK1HTR1ANTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113767092-B | Di-heterocyclic carbonyl substituted dihydropyrazoles, their preparation and their use in medicine | 劲方医药科技(上海)有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-07-28 | — | — | US | disclosed |
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-07-28 | — | — | US | disclosed |
| EP-3967682-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224656-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | NR1H2 1230/4885NR1H3 1007/4885RBP4 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.